Genomic Health Announces Study Results for Oncotype Prostate Diagnostic

Genomic Health announced results Friday from three studies on its Oncotype DX genomic prostate score for the management of prostate health.

Of the 4,000 male patients tested in the first study, results showed a patient risk refinement of 25.2 percent, the company says.

In the second study, results demonstrated that incorporating GPS into prostate cancer management led to a $2,000 cost reduction per patient in the first three post-diagnosis years. These savings were largely the result of increased active surveillance, from rates of 43.8 percent to 69.6 percent.

The third study, conducted on African-American men with prostate cancer, indicated that tumor biology between these ethnic groups and Caucasian males were similar. — Jason Scott